Analyst Research

Report Title Price
Provider: S&P Capital IQ Quantitative Report
Provider: Pechala's Reports
Provider: Reuters Investment Profile
Provider: Thomson Reuters Stock Report

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Flamel Technologies SA receives Class 1 response designation for second NDA

Monday, 16 Jun 2014 08:00am EDT 

Flamel Technologies SA:Receives a Prescription Drug User Fee Act (PDUFA) date of Aug. 6 from the U.S. Food and Drug Administration (FDA) for its second New Drug Application.Flamel's second NDA for an Unapproved Marketed Drug. 

Company Quote

0.3 +2.04%
29 Aug 2014